Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market is segmented By Diagnosis Method (linical Assessment, Imaging Techniques, Laboratory Tests), By Severity-Based Diagnosis (GOLD 1–4 Classification, Groups A–D Classification), By Molecule Type (Monoclonal Antibody , Peptides, Polymer, Small molecule, Gene therapy), By Product (Mono, Combination, Mono/Combination), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned.
Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market Size
Market Size in USD
CAGR4.9%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 4.9% |
| Market Concentration | Medium |
| Major Players | GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, Novartis, Teva Pharmaceuticals |
please let us know !
Chronic Obstructive Pulmonary Disease (COPD) Diagnosis Market Analysis
The chronic obstructive pulmonary disease (COPD) diagnosis market is estimated to be valued at USD 2.18 billion in 2024 and is expected to reach USD 3.05 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031. Market growth can be attributed to the growing geriatric population which are more susceptible to COPD, increasing pollution levels leading to higher incidence of COPD, and availability of more accurate diagnostic tests to detect early stages of COPD.